ArticleTranslational pediatrics2025
Preliminary study on the application of percutaneous patent foramen ovale (PFO) closure in the treatment of children with PFO and severe migraine.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management.MedComm · 2026Review
- Transcatheter Patent Foramen Ovale Closure and Complete Remission of Migraine in Children: A Single-Center Retrospective Cohort Study.Pediatric cardiology · 2026Article
- Patent Foramen Ovale in Children: A Review of Epidemiological Characteristics, Natural Course, and Intervention Strategies.Children (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Numerous studies have shown that patent foramen ovale (PFO) is closely associated with migraine and PFO closure can significantly relieve migraine in adults. However, there are limited data on children. Therefore, this study aims to investigate the role of percutaneous PFO closure in children with PFO and severe migraine, thereby providing theoretical evidence for performing this procedure in the pediatric population. Methods: In this study, we conducted a retrospective analysis of the clinical data from 46 children with PFO and severe migraine admitted to our hospital between September 2021 and October 2023 and assessed the relief of migraine after percutaneous PFO closure. Results: All 46 children with PFO had severe migraine preoperatively. The PFO was determined by transthoracic echocardiography (TTE) and right heart contrast echocardiography suggested the presence of a significant right-to-left shunt (RLS). No residual shunt and complications were observed in all the children after intervention. Before PFO closure, every child experienced repeated migraines. Follow-up data for all patients were obtained by telephone, WeChat, or outpatient visits at 1, 6, 12, and 24 months after PFO closure. The migraine was significantly alleviated in 43 children, while three others experienced no change. There was a significant reduction in the frequency, duration, Visual Analogue Scale (VAS) score and Headache Impact Test-6 (HIT-6) score after PFO closure. Conclusions: Percutaneous PFO closure may be considered for children with PFO and severe migraine who have not responded to other treatments, after excluding other headache causes. In some children, this procedure may significantly improve headache symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.